ExSight Ventures β Full Portfolio
21 tracked investments Β· listed companies and verified rows first
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)John K Freshley(Executive Officer, Director)Jeffrey A Jamison(Executive Officer)David N Zacks(Executive Officer, Director)
Co-investorsInvest MichiganNovartis Venture FundVisionary VenturesBios PartnersInFocus Capital Partners, LLCJohnson & Johnson Innovation β JJDC+3 more
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)Schalon Newton(Executive Officer)
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsSolasta VenturesAccess BiotechnologyBios PartnersCorrelation VenturesFemHealth VenturesHatteras Venture Partners+2 more
HealthtechIrvine, US
JAMES TAYLOR(Executive Officer)IRVING ROBERT ARMSTRONG(Executive Officer)ROBERT SHIMIZU(Executive Officer)NARESH MANDAVA(Director)
BoardAKITERU FURUKAWA(Director)CLAUDE BENEDICT(Director)
BiotechSan Diego, US
Arthur T Suckow(Executive Officer)Arthur Suckow, Ph.D.(Founder)in
Co-investorsAccess BiotechnologyRA Capital
Implant-free, minimally invasive glaucoma surgery (MIGS) creating microscopic channels in the eye to lower intraocular pressure.
Reinventing the eye exam with binocular OCT-based diagnostic technology.
Torrance, US
Alexander Walsh(Executive Officer, Director)Patrick Welsh(Director)Patrick Walsh(Director)Paul Updike(Executive Officer)Patrick C. Walsh(Director)Richard Castro(Executive Officer)
Co-investorsACTAI VenturesAdjuvoAlliance VenturesAppian Capital AdvisoryArkam VenturesAsia2G Capital+49 more
Horizon Surgical Systems develops assistive microsurgical robotics with real-time 3D multimodal imaging and machine learning to support surgeons performing cataract surgery.
AI & Machine LearningMedical DevicesRobotics
Springer is an academic and scientific publisher with a portfolio of over 2,700 journals and more than 220,000 books, serving researchers, authors, readers, and institutions worldwide.
Media & Entertainment
Co-investorsChanzo Capital
LensGen is an ophthalmic medical device company that has developed Juvene, a curvature-changing fluid-optic intraocular lens designed to treat cataracts and presbyopia.
BiotechHardwareHealthtechMedical DevicesIrvine, US
Ramgopal Rao(Founder & Chief Executive Officer)Shivbir Grewal(Director)
BoardAkiteru Furukawa(Director)Michael Colaco(Director)
Co-investorsLightstone Ventures
Novai develops DARC technology for early detection and intervention of eye and brain diseases, aiming to reduce blindness and disability.
BiotechHealthtechMedical DevicesReading, GB
Co-investorsAnglia Capital GroupZinc
Co-investorsClarendon Fund Managers Ltd.Visionary Ventures
First-in-class optogenetic therapy for retinal diseases; acquired by Allergan.
BiotechAnn Arbor, US
Sean Ainsworth(Executive Officer, Director)
BoardTerry Cross(Director)Kenneth Kousky(Director)Cam Gallagher(Director)George Lasezkay(Director)
Co-investorsBoston Harbor AngelsGREAT LAKES BAY VENTURE
BiotechSpringfield, US
Ramanath Bhandari(Executive Officer)Jeff Olson(Director)
BoardRam Palanki(Director)
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesLongitude CapitalTachyon VenturesThe Column Group
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.
BiotechMedical DevicesBerkeley, US
Wesley Jackson(President, Chief Scientific Officer & Member of the Board)Gregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)
BoardDrew Lanza(Director)in
Co-investorsAngel Physicians FundBerkeley CatalystFirst Spark Ventures, LlcPandect Bioventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.